Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy
about
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirNovel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.Modelling imperfect adherence to HIV induction therapyEffect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenIndinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings.Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatmentPharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.CSF penetration by antiretroviral drugs.Special considerations concerning the use of antiretroviral drugs in children.Indinavir alters regulators of protein anabolism and catabolism in skeletal muscle.Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine.Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
P2860
Q28345258-0E3F0040-7A74-4F5C-94DF-37330D753509Q30564087-0A1FDA9A-BB9F-4E2B-9E9A-0FD188E9DB71Q33523201-8B97CCE1-2FC6-4771-A452-1CF9497BAFE8Q33555851-EDDE5B7F-DE9E-4F9E-A7D5-D2B31070BDD5Q33983697-68D4924A-224A-4DB5-9DE0-7E096718792EQ34113462-95ACBF07-FBD9-4D33-BB1B-A1103D5EC7D5Q36024522-D289A42F-AC16-4830-ABCC-CFD53B5B472DQ36322918-9F506601-7508-494D-855A-A645DE911B8DQ36835807-27744722-36B7-453C-BC94-55B86BD46187Q37392730-51DFEC2F-94D2-4E38-AB1C-3E3C8FCC1E84Q37734814-AE89D59B-04DE-409B-AD2B-6A2F0E2E82CEQ37835819-5EF738B2-6055-4AC0-AF06-E053D372680CQ37866289-EB041BEE-1F37-4887-B0CD-1A016AB44A73Q38060571-D54130A4-00C5-4D4E-B102-03EAA40AE6A8Q40535139-26632EEA-661D-4312-9B6B-EC40696EC054Q42476875-012A73A6-F99E-4967-A2F6-C843D3487411Q42625394-67B95137-2426-4B1F-85A6-208A31872FA0Q43907208-A559B5DF-6CE4-493F-8C29-C9608F25424FQ44909192-ED02025E-42F4-47D0-A0D5-3DF4E66885BAQ45090413-412742A4-FFA8-463C-B293-EAFE4DB85DA7Q45117171-CEBE86E5-F2C0-455F-B350-26AA0194E32EQ46571276-07D4E1A2-4A0E-41A9-A262-C27E4AB3231BQ46964970-A9A947CD-28D9-41C9-BB5D-9B2B1E0BAACB
P2860
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacologic characteristics ...... receiving combination therapy
@ast
Pharmacologic characteristics ...... receiving combination therapy
@en
type
label
Pharmacologic characteristics ...... receiving combination therapy
@ast
Pharmacologic characteristics ...... receiving combination therapy
@en
prefLabel
Pharmacologic characteristics ...... receiving combination therapy
@ast
Pharmacologic characteristics ...... receiving combination therapy
@en
P2093
P2860
P1476
Pharmacologic characteristics ...... receiving combination therapy
@en
P2093
C V Fletcher
N R Calles
R C Brundage
R P Remmel
P2860
P304
P356
10.1128/AAC.44.4.1029-1034.2000
P407
P577
2000-04-01T00:00:00Z